RT-GLP3 – 10mg

Retatrutide – 10mg.

Retatrutide (LY3437943) is a 39-amino-acid synthetic triple receptor agonist engineered from a GIP peptide backbone. It simultaneously activates the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R), and glucose-dependent insulinotropic polypeptide receptor (GIPR) — three pivotal receptors involved in metabolic regulation. Its structure incorporates non-coded residues (Aib2, Aib20, α-MeLeu13) and a C20 fatty diacid conjugation to enhance stability and extend systemic presence through albumin binding. In preclinical models, Retatrutide has been shown to induce cAMP accumulation, decrease plasma glucose levels, and reduce body weight, calorie intake, and fat mass in a dose-dependent manner. Phase 2 clinical data demonstrated significant improvements in glycemic control and robust reductions in bodyweight with a safety profile consistent with existing GLP-1 receptor agonist therapies. Retatrutide represents a next-generation approach in metabolic research, building upon the dual-agonist framework established by compounds like tirzepatide.

Certificate of Analysis – Reta 10mg